Indication
Metastatic Squamous Cell Carcinoma
8 clinical trials
11 products
7 drugs
Product
TQB2618Product
Penpulimab injectionClinical trial
A Randomized, Open, Multicenter Phase 1/Phase 2 Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA StudyStatus: Recruiting, Estimated PCD: 2025-06-01
Product
Sample collectionClinical trial
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Product
PembrolizumabProduct
CarboplatinProduct
PaclitaxelClinical trial
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-07-05
Drug
AN0025Product
IRX-2Clinical trial
A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)Status: Recruiting, Estimated PCD: 2026-05-01
Drug
TBio-4101Drug
mFOLFOX6Product
Platinum based chemotherapyDrug
cyclophosphamideDrug
fludarabineDrug
interleukin-2Clinical trial
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-02-22
Product
ADXS-503Clinical trial
Biomarker Driven Phase 1/1b Trial of ASTX727 and Nivolumab in Patients With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Not yet recruiting, Estimated PCD: 2025-02-28
Product
INQOVIDrug
T-VECClinical trial
Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Product
Tremelimumab